High-Sensitivity Cardiac Biomarker Market
High-Sensitivity Cardiac Biomarker Market By Diagnosis Type (CK-MB, Creatinine Kinase, Myoglobin,Cardiac Troponin) , By End User (Hospitals,Cardiology Clinics,Ambulatory Surgical,Centers,Specialty Clinics)-Global Market Insights 2018 to 2028
Analysis of High-Sensitivity Cardiac Biomarker market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Many people suffer from cardiac problems, which can lead to major cardiac diseases. The use of high-sensitivity cardiac biomarkers provides real-time diagnosis for patients who are suffering from cardiac ischemia, ASC (acute coronary syndrome), and various other cardiac-related problems. The high-sensitivity cardiac biomarker is placed within the blood stream to identify the cardiac problem for checking the damage ratio of the heart, and also to find out the stress level of the heart. The diagnosis that the high-sensitivity cardiac biomarker can make determines the risk of the heart of the patient, which can be very helpful for treatment. A high-sensitivity cardiac biomarker is mostly used for the diagnosis for myoglobin, CK-MB, CK (creatinine kinase), and cardiac troponin, which can be a real-time protection for cardiac patients. The symptoms of cardiac ischemia along with acute coronary syndrome and other cardiac diseases are change in pressure, chest pain, nausea, and others, which can lead to cardiac problems. High-sensitivity cardiac biomarkers are much more effective than any other diagnosis methodology for cardiac problems. These high-sensitivity cardiac biomarkers are done at the point of care for cardiac patients.
High-Sensitivity Cardiac Biomarker Market: Drivers and Restraints
The high-sensitivity cardiac biomarker market is expected to be a growing market over the forecast period, as the cardiac patient pool is high in various geographical regions, which directly boosts the market for high-sensitivity cardiac biomarkers.
According to CDC (Centers for Disease Control and Prevention), approx. 735,000 U.S. citizens are suffer from heart attacks every year. Out of these, around 525,000 experience a first-time heart attack, and approx. 210,000 have already experienced a heart attack in the past. The developed medical systems in some of the regions also directly boosts the market for high-sensitivity cardiac biomarkers. The high cost related to high-sensitivity cardiac biomarkers along with the lack of awareness among cardiac patients and health professionals are the current hindrances for the market for high-sensitivity cardiac biomarkers.
High-Sensitivity Cardiac Biomarker Market: Overview
The global high-sensitivity cardiac biomarker market is estimated to be a growing market, as cardiac-specialized hospitals and clinics are increasing in various regions, which directly boosts the market for high-sensitivity cardiac biomarkers. Industries along with various research organizations are working to develop new variants of high-sensitivity cardiac biomarkers that can be more accurate for monitoring cardiac problems in various age groups.
Among the end users, the hospitals segment holds a major market as the presence is high all the geographical regions and also due to high budget for healthcare segment to enhance the infrastructures in developing countries.
High-Sensitivity Cardiac Biomarker Market: Regional Outlook
Geographically, the global high-sensitivity cardiac biomarker market is segmented into North America, Latin America, Europe, CIS & Russia, Japan, Asia Pacific excluding Japan (APEJ), and the Middle East & Africa (MEA). North America has a major market share, as the number of industry players present is high in the region, along with various reimbursement options, which directly affect the market for high-sensitivity cardiac biomarkers. Europe is expected to experience high growth rate, as the adoption rate for high-sensitivity cardiac biomarkers is increasing among healthcare professionals.
CIS & Russia are expected to experience increasing growth, as the adoption rate is increasing among end users for high-sensitivity cardiac biomarkers. Japan is expected to experience moderate growth, as the ageing population have a high risk of cardiac problems, which directly boosts the market of high-sensitivity cardiac biomarkers. Asia Pacific excluding Japan (APEJ) is expected to experience increasing growth, as the awareness about high-sensitivity cardiac biomarkers is increasing for the diagnosis of cardiac problems, along with the increasing medical infrastructure in various countries. The Middle East & Africa (MEA) is expected to experience slow growth, as the medical infrastructure is developing in these regions, along with the increasing awareness among healthcare professionals.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
High-Sensitivity Cardiac Biomarker Market: Key Players
- Creative Diagnostics
- HyTest Ltd
- Life Diagnostics Inc.
- Bio-Rad Laboratories
- Enzo Life Sciences Inc. (sub. of Enzo Biochem Inc.)
- Randox Laboratories Ltd
- Thermo Fisher Scientific
- Merck KGaA
- among others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators, and governing factors, along with market attractiveness as per segment. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved
- Value Chain
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Regional analysis includes
- North America
- Latin America
- Rest of LATAM
- EU – 4 (Germany, France, Italy, Spain)
- BENELUX (Belgium, Netherlands, Luxemburg)
- NORDIC (Norway, Denmark, Iceland, Sweden)
- Eastern Europe (Poland, Ukraine, Czech Rep., etc.)
- Rest of Europe
- CIS & Russia
- Greater China
- S. Korea
- ASEAN Countries
- Rest of APEJ
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of MEA
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
High-Sensitivity Cardiac Biomarker Market: Segmentation
Tentatively, the global high-sensitivity cardiac biomarker market can be segmented on the basis of diagnosis type and end user.
Based on diagnosis type, the global high-sensitivity cardiac biomarker market is segmented as:
- Creatinine Kinase
- Cardiac Troponin
Based on end user, the global high-sensitivity cardiac biomarker market is segmented as:
- Cardiology Clinics
- Ambulatory Surgical Centers
- Specialty Clinics
- FAQs -
The high-sensitivity cardiac biomarker market size is currently valued at USD 16.04 Billion.
The size of the high-sensitivity cardiac biomarker market is likely to expand at a 14.7% CAGR during the forecast period.
The North America region is likely to lead the high-sensitivity cardiac biomarker market.